TY - JOUR
T1 - HLA-Class II in Latin American patients with type 1 diabetes
AU - Rojas-Villarraga, Adriana
AU - Botello-Corzo, Diana
AU - Anaya, Juan Manuel
N1 - Funding Information:
We are grateful to Gina Rojas, Diana C. Varela for their assistance extracting data, Cecile Dunn for reading the manuscript and Manuel Alfonso Patarroyo for his assistance in Haplotype HLA DQA–DQB predictive model. This work was supported by the School of Medicine and Health Sciences, Universidad del Rosario, Bogotá, Colombia .
Copyright:
Copyright 2011 Elsevier B.V., All rights reserved.
PY - 2010/8
Y1 - 2010/8
N2 - Objective: To identify and estimate the common effect size of HLA-Class II contributing to susceptibility on T1D in Latin America (LA) through a meta-analysis. Methods: A systematic review of the literature searching for all HLA-Class II alleles and susceptibility for T1D case-control studies performed in LA was made up to October 2009. Effect summary ORs and 95% CI were obtained by means of the random effect model. A prediction model that identifies peptides binding to HLA-DR alleles that were significantly associated with T1D throughout the meta-analysis was done. Results: 21 studies were included (1138 cases and 1920 controls). DRB1*0301 (OR: 9.65; 95% CI: 5.69-16.36; p< 0.0001), DRB1*1201 (OR: 4.84; 95% CI: 1.97-11.91; p= 0.001), DQB1*0302 (OR: 4.58; 95% CI: 3.36-6.26; p< 0.0001), DQA1*0301(OR: 3.02; 95% CI: 1.37-6.65; p= 0.0059) and DQB1*0602 (OR: 0.19; 95% CI: 0.11-0.33; p< 0.0001), DRB1*14 (OR: 0.18; 95% CI: 0.06-0.55; p= 0.0024), and DQB1*0501 (OR: 0.47; 95% CI: 0.26-0.83; p= 0.0097) were the most significant alleles associated with T1D. DRB1*0301-DQA1*0501-DQB1*0201 (OR: 13.50; 95% CI: 3.85-47.28; p< 0.0001) and DRB1*1301-DQB1*0603 (OR: 0.25; 95% CI: 0.1-0.65; p= 0.004) were the most significant risk and protective haplotypes associated, respectively. There were peptides binding to significantly HLA-DRB1 alleles and haplotypes found through the meta-analysis from islet cell protein tyrosine phosphatase and glutamic acid decarboxylase. Conclusions: These results strengthen the effect of HLA-Class II on T1D in LA similar to Caucasians regardless of the latitudinal gradient and admixture. The shared chemical characteristics in critical pockets could explain the predisposition to present a "diabetogenic peptide" to T cells in this population.
AB - Objective: To identify and estimate the common effect size of HLA-Class II contributing to susceptibility on T1D in Latin America (LA) through a meta-analysis. Methods: A systematic review of the literature searching for all HLA-Class II alleles and susceptibility for T1D case-control studies performed in LA was made up to October 2009. Effect summary ORs and 95% CI were obtained by means of the random effect model. A prediction model that identifies peptides binding to HLA-DR alleles that were significantly associated with T1D throughout the meta-analysis was done. Results: 21 studies were included (1138 cases and 1920 controls). DRB1*0301 (OR: 9.65; 95% CI: 5.69-16.36; p< 0.0001), DRB1*1201 (OR: 4.84; 95% CI: 1.97-11.91; p= 0.001), DQB1*0302 (OR: 4.58; 95% CI: 3.36-6.26; p< 0.0001), DQA1*0301(OR: 3.02; 95% CI: 1.37-6.65; p= 0.0059) and DQB1*0602 (OR: 0.19; 95% CI: 0.11-0.33; p< 0.0001), DRB1*14 (OR: 0.18; 95% CI: 0.06-0.55; p= 0.0024), and DQB1*0501 (OR: 0.47; 95% CI: 0.26-0.83; p= 0.0097) were the most significant alleles associated with T1D. DRB1*0301-DQA1*0501-DQB1*0201 (OR: 13.50; 95% CI: 3.85-47.28; p< 0.0001) and DRB1*1301-DQB1*0603 (OR: 0.25; 95% CI: 0.1-0.65; p= 0.004) were the most significant risk and protective haplotypes associated, respectively. There were peptides binding to significantly HLA-DRB1 alleles and haplotypes found through the meta-analysis from islet cell protein tyrosine phosphatase and glutamic acid decarboxylase. Conclusions: These results strengthen the effect of HLA-Class II on T1D in LA similar to Caucasians regardless of the latitudinal gradient and admixture. The shared chemical characteristics in critical pockets could explain the predisposition to present a "diabetogenic peptide" to T cells in this population.
UR - http://www.scopus.com/inward/record.url?scp=77955270294&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77955270294&partnerID=8YFLogxK
U2 - 10.1016/j.autrev.2010.05.016
DO - 10.1016/j.autrev.2010.05.016
M3 - Review article
C2 - 20561992
AN - SCOPUS:77955270294
SN - 1568-9972
VL - 9
SP - 666
EP - 673
JO - Autoimmunity Reviews
JF - Autoimmunity Reviews
IS - 10
ER -